History of hypertension and eplerenone in patients with acute myocardial infarction complicated by heart failure

Hypertension

Volumn 52, Issue 2, 2008, Pages 271-278

  Pitt, Bertram ^a,l   Ahmed, Ali ^b   Love, Thomas E ^c   Krum, Henry ^d   Nicolau, Jose ^e   Cardoso, José S ^f   Parkhomenko, Alexander ^g   Aschermann, Michael ^h   Corbalán, Ramon ⁱ   Solomon, Henry ^j   Shi, Harry ^j   Zannad, Faiez ^k  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MONASH UNIVERSITY   (Australia)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

^f UNIVERSITY OF PORTO   (Portugal)

^g Ukranian Strazhesko Institute of Cardiology   (Ukraine)

^h UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

ⁱ PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^j PFIZER INC   (United States)

^k UNIVERSITY HOSPITAL OF NANCY   (France)

^l UNIVERSITY OF MICHIGAN   (United States)

more..

Author keywords

Eplerenone; Heart failure; Hypertension; Morbidity; Mortality; Myocardial infarction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; PLACEBO; ALDOSTERONE ANTAGONIST; DRUG DERIVATIVE; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COUGHING; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG USE; DYSPNEA; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GYNECOMASTIA; HAZARD RATIO; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERURICEMIA; HYPOGLYCEMIA; HYPOKALEMIA; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; MENTAL DISEASE; METABOLIC DISORDER; MORTALITY; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SENSITIVITY ANALYSIS; SKIN APPENDAGE DISEASE; SURVIVAL; TREATMENT OUTCOME; URINARY TRACT DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HEART INFARCTION; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PROBABILITY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STATISTICAL MODEL;

AGED; ALDOSTERONE ANTAGONISTS; CAUSE OF DEATH; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SPIRONOLACTONE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 49849089876     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.109314     Document Type: Article

References (42)

1. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321.
2. Rosenbaum PR, Rubin DB. The central role of propensity score in observational studies for causal effects. Biometrika. 1983;70:41-55.
3. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79: 516-524.
4. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
5. Rubin DB. Using propensity score to help design observational studies: application to the tobacco litigation. Health Services Outcomes Res Methodol. 2001;2:169-188.
6. Ahmed A, Husain A, Love TE, Gambassi G, Dell'Italia LJ, Francis GS, Gheorghiade M, Allman RM, Meleth S, Bourge RC. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J. 2006; 27:1431-1439.
7. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
8. Rosenbaum PR. Sensitivity to hidden bias. In: Rosenbaum PR, ed. Observational Studies. 2nd Ed. New York, NY: Springer-Verlag; 2002: 110-124.
9. Rosenbaum PR. Sensitivity analysis for matching with multiple controls. Biometrika. 1988;75:577-581.
10. Rothwell PM. Treating individuals. 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365:176-186.
11. Tuomilehto J, Salonen JT, Nissinen A. Isolated systolic hypertension and its relationship to the risk of myocardial infarction, cerebrovascular disease and death in a middle-aged population. Eur Heart J. 1984;5: 739-744.
12. Haider AW, Chen L, Larson MG, Evans JC, Chen MH, Levy D. Antecedent hypertension confers increased risk for adverse outcomes after initial myocardial infarction. Hypertension. 1997;30:1020-1024.
13. Richards AM, Nicholls MG, Troughton RW, Lainchbury JG, Elliott J, Frampton C, Espiner EA, Crozier IG, Yandle TG, Turner J. Antecedent hypertension and heart failure after myocardial infarction. J Am Coll Cardiol. 2002;39:1182-1188.
14. Kenchaiah S, Davis BR, Braunwald E, Rouleau JL, Dagenais GR, Sussex B, Steingart RM, Brown EJ Jr, Lamas GA, Gordon D, Bernstein V, Pfeffer MA. Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: insights from the Survival and Ventricular Enlargement Trial. Am Heart J. 2004;148:356-364.
15. Peterson JR, Sharma RV, Davisson RL. Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep. 2006;8: 232-241.
16. Zhou MS, Jaimes EA, Raij L. Vascular but not cardiac remodeling is associated with Superoxide production in angiotensin II hypertension. J Hypertens. 2005;23:1737-1743.
17. Intengan HD, Schiffrin EL. Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension. 2001;38:581-587.
18. Davies MJ. Hypertension and atherosclerotic (ischaemic) heart disease. J Hum Hypertens. 1991;5(suppl 1):23-29.
19. Parodi G, Cairabba N, Santoro GM, Memisha G, Valenti R, Buonamici P, Dovellini EV, Antoniucci D. Heart failure and left ventricular remodeling after reperfused acute myocardial infarction in patients with hypertension. Hypertension. 2006;47:706-710.
20. Kenchaiah S, Pfeffer MA, St John Sutton M, Plappert T, Rouleau JL, Lamas GA, Sasson Z, Parker JO, Geltman EM, Solomon SD. Effect of antecedent systemic hypertension on subsequent left ventricular dilation after acute myocardial infarction (from the Survival and Ventricular Enlargement Trial). Am J Cardiol. 2004;94:1-8.
21. Pitt B. Aldosterone blockade in patients with acute myocardial infarction. Circulation. 2003;107:2525-2527.
22. Yamazaki T, Komuro I, Kudoh S, Zou Y, Shiojima I, Mizuno T, Takano H, Hiroi Y, Ueki K, Tobe K, Kadowaki T, Nagai R, Yazaki Y. Angiotensin II partly mediates mechanical stress-induced cardiac hypertrophy. Circ Res. 1995;77:258-265.
23. Ohtani T, Ohta M, Yamamoto K, Mano T, Sakata Y, Nishio M, Takeda Y, Yoshida J, Miwa T, Okamoto M, Masuyama T, Nonaka Y, Hori M. Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker. Am J Physiol Regul Integr Comp Physiol. 2007;292: R946-R954.
24. Yoshida M, Ma J, Tomita T, Morikawa N, Tanaka N, Masamura K, Kawai Y, Miyamori I. Mineralocorticoid receptor is overexpressed in cardiomyocytes of patients with congestive heart failure. Congest Heart Fail. 2005;11:12-16.
25. Hersel J, Jung S, Mohacsi P, Hullin R. Expression of the L-type calcium channel in human heart failure. Basic Res Cardiol. 2002;97(suppl 1): I4-I10.
26. Lalevee N, Rebsamen MC, Barrere-Lemaire S, Ferner E, Nargeot J, Bénitah JP, Rossier MF. Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes. Cardiovasc Res. 2005;67:216-224.
27. Perrier E, Kerfant BG, Lalevee N, Bideaux P, Rossier MF, Richard S, Gomez AM, Benitah JP. Mineralocorticoid receptor antagonism prevents the electrical remodeling that precedes cellular hypertrophy after myocardial infarction. Circulation. 2004;110:776-783.
28. Zhou S, Cao JM, Ohara T, KenKnight BH, Chen LS, Karagueuzian HS, Chen PS. Torsade de pointes and sudden death induced by thiopental and isoflurane anesthesia in dogs with cardiac electrical remodeling. J Cardiovasc Pharmacol Ther. 2002;7:39-43.
29. Chen PS, Chen LS, Cao JM, Sharifi B, Karagueuzian HS, Fishbein MC. Sympathetic nerve sprouting, electrical remodeling and the mechanisms of sudden cardiac death. Cardiovasc Res. 2001;50:409-416.
30. Shroff SC, Ryu K, Martovitz NL, Hoit BD, Stambler BS. Selective aldosterone blockade suppresses atrial tachyarrhythmias in heart failure. J Cardiovasc Electrophysiol. 2006;17:534-541.
31. Boixel C, Gavillet B, Rougier JS, Abriel H. Aldosterone increases voltage-gated sodium current in ventricular myocytes. Am J Physiol Heart Circ Physiol. 2006;290:H2257-H2266.
32. Healey JS, Morillo CA, Connolly SJ. Role of the renin-angiotensin- aldosterone system in atrial fibrillation and cardiac remodeling. Curr Opin Cardiol. 2005;20:31-37.
33. Benitah JP, Vassort G. Aldosterone upregulates Ca(2+) current in adult rat cardiomyocytes. Circ Res. 1999;85:1139-1145.
34. Nishiyama A, Yao L, Nagai Y, Miyata K, Yoshizumi M, Kagami S, Kondo S, Kiyomoto H, Shokoji T, Kimura S, Kohno M, Abe Y. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 2004;43:841-848.
35. Rude MK, Duhaney TA, Kuster GM, Judge S, Heo J, Colucci WS, Siwik DA, Sam F. Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes. Hypertension. 2005;46:555-561.
36. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation. 2003;108:2400-2406.
37. Thai HM, Do BQ, Tran TD, Gaballa MA, Goldman S. Aldosterone antagonism improves endothelial-dependent vasorelaxation in heart failure via upregulation of endothelial nitric oxide synthase production. J Card Fail. 2006;12:240-245.
38. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH. Effects of eplerenone. enalapril. and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108:1831-1838.
39. Packer M. Potential role of potassium as a determinant of morbidity and mortality in patients with systemic hypertension and congestive heart failure. Am J Cardiol. 1990;65:45E-51E; discussion 52E.
40. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004;43:155-161.
41. Srivastava TN, Young DB. Impairment of cardiac function by moderate potassium depletion. J Card Fail. 1995;1:195-200.
42. Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, Pitt B. A propensity matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J. 2007;28:1334-1143.